Study S002339

SIGNAL - Body Fluid Proteome SIGnatures for persoNALised Intervention to Prevent Cardiovascular and Renal Complications in Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06954090
Acronym: SIGNAL
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: ENROLLING_BY_INVITATION
Enrollment: 50
Start: 2025-11-20
Primary completion: 2026-11-30
Lead sponsor: Steno Diabetes Center Copenhagen
Conditions: Type 2 DM; Type 2 DM /Diabetic Nephropathy; Albuminuria
Interventions: DRUG:Semaglutide, 1.34 mg/mL; DRUG:Finerenone Oral Tablet; DRUG:Dapagliflozin (DAPA)
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: CTIS:2024-518682-95-00

Registered primary outcomes

Proteomic feasibility [2 weeks from sampling]
Evaluation of medical treatment [3 weeks from sampling]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.